Bristol Myers Squibb's Strong Performance in Q3
Bristol Myers Squibb & Co (NYSE: BMY) delivered an impressive performance in the third quarter, achieving revenues of $11.89 billion. This surpassed market expectations of $11.28 billion, marking an 8% increase year-over-year, or a 10% increase when adjusted for foreign exchange fluctuations. The primary contributors to this growth were its Growth Portfolio and the popular anticoagulant, Eliquis.
Growth Portfolio Insights
The remarkable growth in the Growth Portfolio saw worldwide revenues rise to $5.81 billion, up from $4.95 billion in the previous year. This translates to an 18% growth on a reported basis, or 20% adjusting for currency impacts. The key drivers behind this revenue surge included heightened demand for innovative therapies such as Reblozyl, Breyanzi, Camzyos, and Opdualag.
Revenue Contributions from Key Products
Opdivo, another flagship drug, reported sales of $2.36 billion, reflecting a growth of 4% due to increased volume globally. Meanwhile, sales of Abecma soared by 33%, reaching $124 million. Reblozyl, an anemia treatment, saw an outstanding sales increase of 80%, generating $447 million in the third quarter.
Legacy Portfolio Performance
Turning to the Legacy Portfolio, revenues were $6.08 billion, slightly up from $6.02 billion a year earlier, showing a growth of 1%. This performance was largely supported by the rising popularity of Eliquis. Sales for this drug increased to $3 billion, up from $2.71 billion the previous year, though this success was tempered by a decline in Sprycel sales driven by generic competition.
Financial Metrics and Future Expectations
Bristol Myers reported an adjusted earnings per share (EPS) of $1.80, which although lower than the $2.00 from the previous year, exceeded the consensus estimate of $1.49. The company is also implementing cost-saving initiatives aimed at achieving internal savings of approximately $1.5 billion by 2025.
Upcoming Product Launches
The company is excited about the launch of its newly approved schizophrenia medication, Cobenfy. The rollout is anticipated to reach a majority of the market by the second half of 2025, showcasing Bristol Myers' commitment to innovation in therapeutic options.
Guidance for 2024
Bristol Myers Squibb has provided an optimistic guidance for 2024, forecasting adjusted EPS between $0.75 and $0.95, which is an improvement from earlier predictions of $0.60 to $0.90. The consensus EPS estimate stands at $0.71. Additionally, the company expects overall revenue growth of around 6% for the year ahead, which is a positive shift from the previously anticipated single-digit growth.
Stock Performance and Market Outlook
As of the last market check, BMY stock experienced a robust increase of 5.18%, trading at $55.39. This upward trend in stock performance reflects market confidence in Bristol Myers’ strategic direction and financial health.
Frequently Asked Questions
What were Bristol Myers Squibb’s Q3 revenues?
Bristol Myers Squibb reported third-quarter revenues of $11.89 billion, exceeding market estimates.
Which products contributed to the revenue growth?
Growth was mainly driven by higher demand for therapies such as Reblozyl, Opdivo, and Eliquis.
What is the guidance for 2024 adjusted EPS?
The company forecasts adjusted EPS for 2024 to be between $0.75 and $0.95, an improvement from prior estimates.
What impact has generic competition had?
Generic competition has negatively affected sales of Sprycel, though Eliquis continues to perform strongly.
How did the stock perform recently?
BMY stock rose by 5.18%, indicating a positive market response to the company’s performance and outlook.
